DE69217614D1 - Hybride, lösliche und nicht gespaltene gp160-variante - Google Patents
Hybride, lösliche und nicht gespaltene gp160-varianteInfo
- Publication number
- DE69217614D1 DE69217614D1 DE69217614T DE69217614T DE69217614D1 DE 69217614 D1 DE69217614 D1 DE 69217614D1 DE 69217614 T DE69217614 T DE 69217614T DE 69217614 T DE69217614 T DE 69217614T DE 69217614 D1 DE69217614 D1 DE 69217614D1
- Authority
- DE
- Germany
- Prior art keywords
- hiv
- region
- strain
- soluble
- derived
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 241000713772 Human immunodeficiency virus 1 Species 0.000 abstract 6
- 208000031886 HIV Infections Diseases 0.000 abstract 5
- 150000001413 amino acids Chemical class 0.000 abstract 2
- 230000002209 hydrophobic effect Effects 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 230000006337 proteolytic cleavage Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Curing Cements, Concrete, And Artificial Stone (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Control Of Vehicle Engines Or Engines For Specific Uses (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR919105392A FR2676071B1 (fr) | 1991-05-02 | 1991-05-02 | Nouveau variant gp160 non-clivable, soluble, de forme hybride. |
| PCT/FR1992/000394 WO1992019742A1 (fr) | 1991-05-02 | 1992-04-30 | NOUVEAU VARIANT gp160 NON-CLIVABLE, SOLUBLE, DE FORME HYBRIDE |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE69217614D1 true DE69217614D1 (de) | 1997-04-03 |
| DE69217614T2 DE69217614T2 (de) | 1997-07-10 |
Family
ID=9412448
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69217614T Expired - Lifetime DE69217614T2 (de) | 1991-05-02 | 1992-04-30 | Hybride, lösliche und nicht gespaltene gp160-variante |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US6261799B1 (de) |
| EP (1) | EP0541753B1 (de) |
| JP (1) | JP3453611B2 (de) |
| AT (1) | ATE149203T1 (de) |
| CA (1) | CA2086509C (de) |
| DE (1) | DE69217614T2 (de) |
| DK (1) | DK0541753T3 (de) |
| ES (1) | ES2099257T3 (de) |
| FR (1) | FR2676071B1 (de) |
| GR (1) | GR3023070T3 (de) |
| SG (1) | SG44828A1 (de) |
| WO (1) | WO1992019742A1 (de) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2107732C (en) * | 1992-10-06 | 2003-04-08 | Lutz G. Gurtler | Retrovirus from the hiv group and its use |
| EP0679187B2 (de) * | 1993-01-16 | 2001-07-04 | SCHAWALLER, Manfred | Verfahren zur gewinnung nativer, oligomerer, glykosylierter ektodomänen viraler membranproteine, deren verwendung, insbesondere als impfstoff gegen hiv |
| DE4405810A1 (de) | 1994-02-23 | 1995-08-24 | Behringwerke Ag | Von einem Retrovirus aus der HIV-Gruppe abgeleitete Peptide und deren Verwendung |
| AU2001233340B2 (en) | 2000-02-10 | 2006-05-04 | Panacos Pharmaceuticals, Inc. | Assay for detection of viral fusion inhibitors |
| WO2009011912A1 (en) * | 2007-07-18 | 2009-01-22 | Bristol-Myers Squibb Company | A composition for treating hiv comprising virus-like particles |
| AP2013007180A0 (en) * | 2011-04-25 | 2013-10-31 | Advanced Bioscience Lab Inc | Truncated HIV envelope proteins (ENV), methods andcompositions related thereto |
| CN104853770A (zh) | 2012-07-06 | 2015-08-19 | 诺华股份有限公司 | 免疫原性组合物及其应用 |
| WO2016196471A1 (en) | 2015-06-02 | 2016-12-08 | Cooper Human Systems Llc | Methods and compositions for treatment of hiv infection |
| TW201922800A (zh) * | 2017-11-17 | 2019-06-16 | 美商格里佛診斷方法股份有限公司 | 新穎哺乳動物表現的人類免疫缺乏病毒外套膜蛋白抗原 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2606029B2 (fr) * | 1986-04-08 | 1989-02-03 | Transgene Sa | Vecteur viral et adn recombinant codant pour une glycoproteine du virus agent causal du s.i.d.a., culture cellulaire infectee par ce vecteur, procede de preparation de la glycoproteine, glycoproteine obtenue, vaccin et anticorps obtenus |
| US5169763A (en) * | 1986-04-08 | 1992-12-08 | Transgene S.A., Institut Pasteur | Viral vector coding glycoprotein of HIV-1 |
| EP0272858A3 (de) * | 1986-12-15 | 1989-07-12 | Repligen Corporation | Rekombinante HIV-Hüllen-Proteine, hergestellt in Insektenzellen |
| FR2620030B1 (fr) * | 1987-09-07 | 1990-03-23 | Transgene Sa | Vecteur d'expression des proteines du virus hiv-2, un agent causal du sida, culture cellulaire infectee ou transformee par ce vecteur, proteines obtenues, vaccin et anticorps obtenus |
| IL89567A0 (en) * | 1988-03-28 | 1989-09-10 | Univ Leland Stanford Junior | Mutated hiv envelope protein |
| CA2003383A1 (en) * | 1988-11-23 | 1990-05-23 | Sushil G. Devare | Synthetic dna derived recombinant hiv antigens |
| WO1990012880A1 (en) * | 1989-04-18 | 1990-11-01 | Applied Biotechnology, Inc. | Generation of hybrid genes and proteins by virus-mediated recombination |
| FR2650954B1 (fr) * | 1989-08-18 | 1992-02-28 | Pasteur Institut | Composition resultant de la reunion d'un epitope b de la glycoproteine d'enveloppe d'un retrovirus du type iv et d'un epitope t issu d'une proteine distincte codee par ce retrovirus et leur application a la production d'anticorps protecteurs contre le sida |
| GB8923123D0 (en) * | 1989-10-13 | 1989-11-29 | Connaught Lab | A vaccine for human immunodeficiency virus |
| IE904083A1 (en) * | 1989-11-13 | 1991-05-22 | Cambridge Biotech Corp | Diagnostic proteins to test for more than one antibody |
| EP0527760B1 (de) * | 1990-04-03 | 1995-07-19 | Genentech, Inc. | Methoden und zusammensetzungen zur impfung gegen hiv |
-
1991
- 1991-05-02 FR FR919105392A patent/FR2676071B1/fr not_active Expired - Fee Related
-
1992
- 1992-04-30 AT AT92910881T patent/ATE149203T1/de active
- 1992-04-30 CA CA002086509A patent/CA2086509C/fr not_active Expired - Lifetime
- 1992-04-30 WO PCT/FR1992/000394 patent/WO1992019742A1/fr not_active Ceased
- 1992-04-30 DE DE69217614T patent/DE69217614T2/de not_active Expired - Lifetime
- 1992-04-30 ES ES92910881T patent/ES2099257T3/es not_active Expired - Lifetime
- 1992-04-30 DK DK92910881.9T patent/DK0541753T3/da active
- 1992-04-30 EP EP92910881A patent/EP0541753B1/de not_active Expired - Lifetime
- 1992-04-30 US US07/956,483 patent/US6261799B1/en not_active Expired - Lifetime
- 1992-04-30 SG SG1996008345A patent/SG44828A1/en unknown
- 1992-04-30 JP JP50983392A patent/JP3453611B2/ja not_active Expired - Lifetime
-
1995
- 1995-06-07 US US08/472,240 patent/US6284248B1/en not_active Expired - Lifetime
-
1997
- 1997-04-08 GR GR970400738T patent/GR3023070T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| FR2676071A1 (fr) | 1992-11-06 |
| SG44828A1 (en) | 1997-12-19 |
| EP0541753A1 (de) | 1993-05-19 |
| ATE149203T1 (de) | 1997-03-15 |
| CA2086509A1 (fr) | 1992-11-03 |
| WO1992019742A1 (fr) | 1992-11-12 |
| CA2086509C (fr) | 2003-07-01 |
| US6261799B1 (en) | 2001-07-17 |
| ES2099257T3 (es) | 1997-05-16 |
| DK0541753T3 (da) | 1997-08-04 |
| JP3453611B2 (ja) | 2003-10-06 |
| FR2676071B1 (fr) | 1994-11-18 |
| JPH05508324A (ja) | 1993-11-25 |
| US6284248B1 (en) | 2001-09-04 |
| EP0541753B1 (de) | 1997-02-26 |
| GR3023070T3 (en) | 1997-07-30 |
| DE69217614T2 (de) | 1997-07-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE380822T1 (de) | Funf-helix protein | |
| NO20025153L (no) | Fremgangsmåter og sammensetninger for å påvirke formering av HIV-1, HIV-2 og SIV | |
| DK1240186T3 (da) | Forbedringer i eller relateret til immunrespons mod HIV | |
| DE3855947D1 (de) | Peptide mit den immunologischen Eigenschaften von HIV-2 | |
| MY136081A (en) | Modified hiv - 1gag p17 peptide and immunogenic composition | |
| ATE135743T1 (de) | Monoklonale menschliche antikörper gegen hiv-i | |
| DE60039036D1 (de) | Hiv-peptide, antigene und impfstoffzusammensetzungen | |
| ATE154610T1 (de) | Synthetische vom hiv-gp120-env-protein abgeleitete peptide und ihre anwendung | |
| DE69217614D1 (de) | Hybride, lösliche und nicht gespaltene gp160-variante | |
| Nygren et al. | 95-and 25-kDa fragments of the human immunodeficiency virus envelope glycoprotein gp120 bind to the CD4 receptor. | |
| WO1993018055A3 (en) | Peptides stimulating cytotoxic lymphocytes respone to hiv-1 gp160 | |
| DE69231705D1 (de) | Gag-Env Fusion-Antigen aus HIV | |
| EP1104310A4 (de) | Expression und charakterisierung eines hiv-1 hüllproteins, das mit einer breitreaktiven neutralisierenden antikörperantwort assoziiert ist. | |
| ES8800358A1 (es) | Un procedimiento para preparar un polipeptido hibrido. | |
| KR890009415A (ko) | 항 비루스성 화합물 및 그 제조방법 | |
| ES2095899T3 (es) | Peptidos de la proteina gag de vih, su preparacion y uso. | |
| DK1043974T3 (da) | Liposomer indeholdende flergrenede peptidkonstruktioner til anvendelse mod human immundefektvirus | |
| RU2000106709A (ru) | Пептиды-имитаторы консервативного эпитопа белка gp41 вируса иммунодефицита человека типа 1, узнаваемого вируснейтрализующими моноклональными антителами 2f5 | |
| WO2000058438A3 (en) | Conformationally constrained peptides | |
| RU2221873C2 (ru) | Способ получения каталитических антител (варианты), антигены для иммунизации и нуклеотидная последовательность | |
| DK284389D0 (da) | Precursorantigener | |
| KR890003946A (ko) | 인간 면역 결핍 비루스 타입1의 항원의 제조방법 및 진단 및 치료제로서의 이의 용도 | |
| OA08716A (fr) | Peptides susceptibles d'être reconnus par des anticorps induits contre des retrovirus d'immunodéficience humaine (virus HIV), leurs applications au diagnostic des infections dues à certains de ces virus et, le cas échéant, à la vaccination contre le sida. | |
| Ivanoff et al. | Human immunodeficiency virus antigen. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition | ||
| R071 | Expiry of right |
Ref document number: 541753 Country of ref document: EP |